1. Figure 5 Classification of immunotherapies
Figure 5 | Classification of immunotherapies. The diverse immunotherapeutic interventions have been classified according to their modality (pink, orange, yellow, green, grey, blue or violet) and primary effect (class 1 to 9). *High-capacity adenoviruses might incorporate several transgenes for intratumour expression of one, two or three different mAbs, or one cytokine plus one or two mAbs. ‡Transgenes encoding potentially toxic molecules should preferably be placed under the control of an inducible promoter. §Deliverable by intratumour gene transfer. Abbreviations: CIK, cytokine-induced killer cell; CTLA-4, cytotoxic T-lymphocyte protein 4; CXCL10, C-X-C motif chemokine 10; GITR, TNF receptor superfamily member 18; GPC3, glypican-3; LAG-3, lymphocyte activation gene 3; mAb, monoclonal antibody; NG-CAR T cell, new-generation chimeric antigen receptor T cell; NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; TCR, T-cell receptor; TCR-mod, modified TCR; TH1, type 1 T helper cell; TIL, tumour-infiltrating lymphocyte; TIM-3, T-cell immunoglobulin and mucin domain-containing protein-3; VEGF, vascular endothelial growth factor.
Prieto, J. et al. (2015) Immunological landscape and immunotherapy of hepatocellular carcinoma
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro